AOD-9604 (Anti-Obesity Drug 9604 / Tyr-hGH 177-191)

✅ Stabilised hGH 176-191 C-terminal lipolytic fragment (N-terminal Tyr extension) ✅ Developed by Metabolic Pharmaceuticals Ltd (Monash University, late 1990s) ✅ GHR-decoupled — no IGF-1, no JAK2/STAT5, no growth-axis engagement ✅ Lipolytic + anti-lipogenic; β3-AR-dependent (mechanism incompletely characterised) ✅ ~4 min plasma half-life; Phase IIb obesity trial failed (2007); MW 1815.1, CAS 221231-10-3 AOD-9604 contains synthetic Tyr-hGH(177-191) research peptide.